Rifapentine, an antibiotic used to treat tuberculosis, was developed in the 1980s and approved for medical use in the late 1990s. Its history is marked by its effectiveness in treating latent and active tuberculosis, as well as its long-acting properties that allow intermittent dosing. Rifapentine, a rifamycin-class antibiotic, was approved in the United States in 1998 and is included in multiple combination regimens for tuberculosis therapy. Its development featured clinical studies focused on optimizing dosing schedules and safety monitoring to minimize adverse effects and drug interactions.
BRAND NAMES
Priftin – the most widely recognized brand.
MECHANISM OF ACTION
Rifapentine is a rifamycin antibiotic that inhibits bacterial DNA-dependent RNA polymerase by binding to its beta-subunit. This blocks RNA synthesis, preventing protein production and leading to bacterial death. It is bactericidal against Mycobacterium tuberculosis and is used in combination with other antitubercular drugs to reduce the risk of resistance. Its long half-life allows for intermittent dosing in tuberculosis treatment.
PHARMACOKINETICS
Absorption
Rifapentine is well absorbed after oral administration, reaching peak plasma concentrations in about 5 to 6 hours. Its absorption is improved when taken with food, so it is usually recommended to take it with a meal. The drug shows linear pharmacokinetics across the usual therapeutic dose range.
Distribution
Rifapentine has a moderate volume of distribution, typically around 0.7 to 1.0 L/kg. This allows the drug to distribute effectively into lung tissue, liver, kidneys, and macrophages, which are key sites for Mycobacterium tuberculosis infection.
Metabolism
Rifapentine is mainly metabolized in the liver through deacetylation, forming its active metabolite, 25-desacetyl rifapentine, which contributes to its antibacterial activity. Both the parent drug and metabolite can induce hepatic enzymes, potentially affecting the metabolism of other medications when used concurrently.
Elimination
Rifapentine and its metabolites are mainly excreted in the feces, with a smaller portion eliminated in the urine. The drug has a long elimination half-life of around 13 hours, which supports once- or twice-weekly dosing in tuberculosis treatment. Liver function can affect its clearance, while renal impairment has little impact.
PHARMACODYNAMICS
Rifapentine is a bactericidal antibiotic that works by inhibiting DNA-dependent RNA polymerase in Mycobacterium tuberculosis, blocking RNA synthesis and protein production, which leads to bacterial death. Its long half-life allows for sustained activity, making it suitable for intermittent dosing. Rifapentine is most effective when used in combination with other antitubercular drugs to prevent resistance and improve treatment outcomes.
ADMINISTRATION
Rifapentine is given orally in tablet form, usually once or twice weekly as part of combination therapy for tuberculosis. It should be taken with food to improve absorption, and tablets should be swallowed whole. Adhering to the prescribed schedule is important to maintain effectiveness and prevent drug resistance.
DOSAGE AND STRENGTH
Adults: 600 mg orally once weekly in combination with isoniazid for latent tuberculosis; in some regimens, 900 mg may be used for active TB.
Pediatric: Dose is weight-based, typically 15–20 mg/kg once weekly.
Formulation: 150 mg tablets.
DRUG INTERACTIONS
Rifapentine induces liver enzymes, which can reduce the effectiveness of oral contraceptives, anticoagulants, antiretrovirals, and other CYP-metabolized drugs. Patients should inform their doctor about all medications before use.
FOOD INTERACTIONS
Rifapentine should be taken with food, as this improves its absorption andbioavailability. There are no other significant food interactions reported, so meals do not need to be restricted aside from enhancing drug uptake.
CONTRAINDICATIONS
Rifapentine is contraindicated in hypersensitivity to rifamycins and in severe liver impairment. Caution is needed with drugs dependent on CYP3A metabolism.
SIDE EFFECTS
Nausea
Vomiting
Loss of appetite
Fatigue
Headache
Hepatotoxicity
Hypersensitivity reactions
Blood disorders (e.g., thrombocytopenia, anemia)
OVER DOSE
Overdose may cause nausea, vomiting, abdominal pain, fatigue, and liver enzyme elevations. Treatment is supportive, and medical attention should be sought.
TOXICITY
Rifapentine has a relatively low toxicity profile when used at recommended doses, but excessive or prolonged use can lead to hepatotoxicity, hypersensitivity reactions, or blood disorders such as anemia or thrombocytopenia. Toxicity management involves discontinuing the drug, monitoring liver function and blood counts, and providing supportive careas needed.
